Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Telix Pharmaceuticals ( (AU:TLX) ) has issued an update.
Telix Pharmaceuticals announced the release of 1,649,037 ordinary shares from voluntary escrow, which were initially issued as part of the acquisition of Lightpoint Medical’s SENSEI® radio-guided surgery business. This release, scheduled for November 3, 2025, marks a significant step in the integration of Lightpoint Medical’s technologies, potentially enhancing Telix’s market position in the field of minimally invasive and robotic-assisted surgery.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$23.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Headquartered in Melbourne, Australia, Telix operates internationally in the United States, United Kingdom, Brazil, Canada, Europe, and Japan. The company is dedicated to addressing significant unmet medical needs in oncology and rare diseases, with a portfolio of clinical and commercial stage products.
Average Trading Volume: 3,035,411
Technical Sentiment Signal: Sell
Current Market Cap: A$5.74B
For an in-depth examination of TLX stock, go to TipRanks’ Overview page.